Aligos Therapeutics (NASDAQ:ALGS) Announces Quarterly Earnings Results, Misses Estimates By $0.92 EPS

Aligos Therapeutics (NASDAQ:ALGS) posted its earnings results on Wednesday. The company reported ($3.07) earnings per share for the quarter, missing the consensus estimate of ($2.15) by ($0.92), Zacks reports. The firm had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.00 million. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same quarter last year, the business posted ($10.25) earnings per share.

Aligos Therapeutics Stock Up 2.7 %

Shares of NASDAQ:ALGS traded up $0.27 during midday trading on Friday, reaching $10.19. 108,249 shares of the company were exchanged, compared to its average volume of 39,795. The firm has a market cap of $32.61 million, a PE ratio of -0.50 and a beta of 2.11. Aligos Therapeutics has a fifty-two week low of $6.76 and a fifty-two week high of $30.00. The stock has a fifty day simple moving average of $9.81 and a two-hundred day simple moving average of $12.63.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research note on Thursday.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).